Collaborating to advance use of artificial intelligence technologies in preclinical drug discovery & development
Artificial Intelligence technologies can increase the quality and amount of information gained from both human and animal studies, and offer unique opportunities for scientific advancement. Artificial Intelligence represents an opportunity to complement and, in some cases, reduce reliance on animal models in biomedical research and preclinical drug discovery and development.
The 3RsC Artificial Intelligence Initiative is a collaboration between technology developers, end-users, regulators, academics, and other stakeholders in the AI space. It provides a venue for productive interaction between key stakeholders in the industry to advance implementation and qualification of artificial intelligence methods. The 3Rs Collaborative is a US-based non-profit focused on advancing better science – for both humans and animals – through facilitating collaborative 3Rs initiatives.
Our two current co-leads responsible for launching this initiative are Dr. Szczepan Baran and Dr. Weida Tong. They provide leadership, guidance, and tactical advice for this group.
Director of Bioinformatics & Biostatistics, FDA’s National Center for Toxicological Research
We established this initiative in mid 2023 with 10 founding companies. Membership is now open to any relevant individuals who meet our membership criteria.
If you are interested in joining the Artificial Intelligence initiative please send an email with your CV and short statement of interest to laurenyoung@3rc.org
